Akums Drugs Q2 FY27 Revenue Up 31.9% to ₹1,342 Cr, EBITDA Doubles YoY
Akums Drugs reported Q2 FY27 revenue of ₹1,342 crore, up 31.9% YoY. EBITDA surged 106.1% to ₹195 crore. H1 FY27 revenue reached ₹2,509 crore, up 22.9% YoY, with EBITDA up 65.3%. Growth driven by CDMO segment. Company earned EcoVadis Bronze Medal.
The substantial year-on-year growth in revenue and EBITDA, coupled with improved profitability and a positive outlook, indicates a significant positive impact on the company's financial performance and investor perception.
The company reported strong year-on-year growth in revenue and EBITDA, along with significant improvements in profitability. Positive outlook and recognition like the EcoVadis Bronze Medal also contribute to a positive sentiment.
Akums Drugs and Pharmaceuticals Limited has announced its financial results for the second quarter and first half of the fiscal year 2027. For Q2 FY27, the company reported a significant revenue growth of 31.9% year-on-year, reaching ₹1,342 crore, compared to ₹1,018 crore in Q2 FY26. EBITDA more than doubled year-on-year, increasing by 106.1% to ₹195 crore from ₹94 crore, with an improved EBITDA margin of 14.5% from 9.3%. Profit After Tax (PAT) also saw a substantial jump of 168.3% to ₹115 crore from ₹43 crore, with the PAT margin improving to 8.4% from 4.1%. Sequentially, revenue grew by 15.1% and EBITDA by 11.5%.
For the first half of FY27 (H1 FY27), total revenue stood at ₹2,509 crore, a 22.9% increase year-on-year. EBITDA for H1 FY27 grew by 65.3% to ₹369 crore, and PAT increased by 100.7% to ₹216 crore.
The growth was primarily driven by the Contract Development and Manufacturing Organization (CDMO) segment, which contributed 83.1% to the Q2 FY27 revenue and experienced double-digit volume growth. The company also noted robust demand in the CDMO segment and its deepening presence in the Indian Pharmaceutical Market (IPM). The domestic branded formulations segment showed steady year-on-year revenue growth of 8%, with improved profitability sequentially. The international branded formulations business accelerated its growth on both year-on-year and sequential bases. The API segment continued its progress towards EBITDA break-even, while the trade generics segment achieved EBITDA positivity. The company's European CDMO project is progressing as planned, and commercial supplies for the Zambia initiative are expected from the Indian plant in Q4 FY27, with revenue booking in Q1 FY28.
Akums also announced it has earned an EcoVadis Bronze Medal, placing it among the top 35% of global assessed companies. The company remains optimistic about delivering positive results and is committed to creating long-term shareholder value.
What to do with a filing like this
Akums Drugs and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Akums Drugs and Pharmaceuticals Limited. Read the original for the full detail.